Seattle Genetics Presents Data On SGN-70, A Humanized Monoclonal Antibody Targeting CD70

Seattle Genetics, Inc. (Nasdaq: SGEN) today presented preclinical data on SGN-70 at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco, California. SGN-70 is a humanized monoclonal antibody targeting CD70 that is in development as a novel therapy for autoimmune diseases. Seattle Genetics is currently conducting a phase I trial to assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy volunteers.